Table 1 Selected baseline demographics of randomized populations from ICARIA-MM and IKEMA.
ICARIA-MM | IKEMA | |||
|---|---|---|---|---|
Isatuximab plus pomalidomide plus dexamethasone (n = 154) | Pomalidomide plus dexamethasone (n = 153) | Isatuximab plus carfilzomib plus dexamethasone (n = 179) | Carfilzomib plus dexamethasone (n = 123) | |
Age (years) | ||||
Median | 68 (60–74) | 66 (59–71) | 65 (55–70) | 63 (57–70) |
<65 | 54 (35%) | 70 (46%) | 88 (49%) | 66 (54%) |
≥65 to <75 | 68 (44%) | 54 (35%) | 74 (41%) | 47 (38%) |
≥75 | 32 (21%) | 29 (19%) | 17 (9%) | 10 (8%) |
Gender | ||||
Female | 65 (42%) | 83 (54%) | 78 (44%) | 55 (45%) |
Male | 89 (58%) | 70 (46%) | 101 (56%) | 68 (55%) |
eGFRa <60 mL/min per 1.73 m2 | 55/142 (39%) | 49/145 (34%) | 43/165 (26%) | 18/111 (16%) |
Previous autologous stem-cell transplant | 83 (54%) | 90 (59%) | 116 (65%) | 69 (56%) |
Time from initial diagnosis of multiple myeloma to randomization, years | 4.5 (2.6–7.2) | 4.1 (2.9–7.0) | 3.2 (2.0–5.5) | 3.3 (2.1–5.8) |
Number of previous lines of therapy | 3 (2–4) | 3 (2–4) | 2 (1–2) | 2 (1–3) |
Previous therapy | ||||
Alkylating agents | 139 (90%) | 148 (97%) | 169 (94%) | 101 (82%) |
Proteasome inhibitors | 154 (100%) | 153 (100%) | 166 (93%) | 105 (85%) |
Immunomodulatory agents | 154 (100%) | 153 (100%) | 136 (76%) | 100 (81%) |
Monoclonal antibodies | 0 | 0 | 5 (3%) | 1 (1%) |
Refractory to treatment | ||||
Last regimen | 150 (97%) | 151 (99%) | 89 (50%) | 73 (59%) |
Immunomodulatory agent | 147 (95%) | 144 (94%) | 78 (44%) | 58 (47%) |
Proteasome inhibitor | 118 (77%) | 115 (75%) | 56 (31%) | 44 (36%) |
Lenalidomide | 144 (94%) | 140 (92%) | 57 (32%) | 42 (34%) |
Lenalidomide in last previous regimen | 93 (60%) | 88 (58%) | 36 (20%) | 31 (25%) |
